Cantargia Beheer

Beheer criteriumcontroles 2/4

De CEO Cantargia is Goran Forsberg, benoemd in Jun2014, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 5.40M, bestaande uit 44% salaris en 56% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.17% van de aandelen van het bedrijf, ter waarde SEK 551.58K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4.1 jaar.

Belangrijke informatie

Goran Forsberg

Algemeen directeur

SEK 5.4m

Totale compensatie

Percentage CEO-salaris	44.0%
Dienstverband CEO	10.4yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

Analyse CEO-vergoeding

Hoe is Goran Forsberg's beloning veranderd ten opzichte van Cantargia's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 194m
Jun 30 2024	n/a	n/a	-SEK 228m
Mar 31 2024	n/a	n/a	-SEK 241m
Dec 31 2023	SEK 5m	SEK 2m	-SEK 280m
Sep 30 2023	n/a	n/a	-SEK 299m
Jun 30 2023	n/a	n/a	-SEK 293m
Mar 31 2023	n/a	n/a	-SEK 330m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 372m
Sep 30 2022	n/a	n/a	-SEK 385m
Jun 30 2022	n/a	n/a	-SEK 419m
Mar 31 2022	n/a	n/a	-SEK 411m
Dec 31 2021	SEK 5m	SEK 2m	-SEK 367m
Sep 30 2021	n/a	n/a	-SEK 319m
Jun 30 2021	n/a	n/a	-SEK 255m
Mar 31 2021	n/a	n/a	-SEK 206m
Dec 31 2020	SEK 6m	SEK 2m	-SEK 173m
Sep 30 2020	n/a	n/a	-SEK 153m
Jun 30 2020	n/a	n/a	-SEK 139m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 4m	SEK 2m	-SEK 111m
Sep 30 2019	n/a	n/a	-SEK 102m
Jun 30 2019	n/a	n/a	-SEK 98m
Mar 31 2019	n/a	n/a	-SEK 101m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 91m
Sep 30 2018	n/a	n/a	-SEK 78m
Jun 30 2018	n/a	n/a	-SEK 68m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 60m

Compensatie versus markt: De totale vergoeding ($USD 489.35K ) Goran } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 235.48K ).

Compensatie versus inkomsten: De vergoeding van Goran is gestegen terwijl het bedrijf verliesgevend is.

CEO

Goran Forsberg (61 yo)

10.4yrs

Tenure

SEK 5,404,000

Compensatie

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Goran Forsberg	Chief Executive Officer	10.4yrs	SEK 5.40m	0.17% SEK 551.6k
Thoas Fioretos	Founder & Scientific Advisor	no data	SEK 355.00k	geen gegevens
Marcus Järås	Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Kjell Sjöström	Founder	no data	geen gegevens	geen gegevens
Patrik Renblad	Chief Financial Officer	1.4yrs	geen gegevens	geen gegevens
David Liberg	Chief Scientific Officer	1.4yrs	geen gegevens	geen gegevens
Nina Valkama	Executive Assistant of Administration & Finance	2.9yrs	geen gegevens	geen gegevens
Dominique Tersago	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens
Antonius Berkien	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Johanna Christensen	Financial Controller	2.9yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CANTA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gunnar Magnus Severus Persson	Independent Chairman of the Board	8.8yrs	SEK 854.00k	geen gegevens
Damian Marron	Independent Director	3.5yrs	SEK 350.00k	geen gegevens
Anders Martin-Lof	Independent Director	6.5yrs	SEK 473.00k	geen gegevens
Magnus Nilsson	Independent Director	3.5yrs	SEK 342.00k	geen gegevens
Flavia Borellini	Independent Director	4.1yrs	SEK 550.00k	geen gegevens

4.1yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CANTA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Cantargia Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Chief Executive Officer recently bought kr104k worth of stock

Chief Executive Officer recently bought kr103k worth of stock

Recent updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy